1. Home
  2. IMRN vs SPPL Comparison

IMRN vs SPPL Comparison

Compare IMRN & SPPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • SPPL
  • Stock Information
  • Founded
  • IMRN 1994
  • SPPL 2016
  • Country
  • IMRN Australia
  • SPPL Singapore
  • Employees
  • IMRN N/A
  • SPPL N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • SPPL
  • Sector
  • IMRN Health Care
  • SPPL
  • Exchange
  • IMRN Nasdaq
  • SPPL Nasdaq
  • Market Cap
  • IMRN 9.2M
  • SPPL 9.8M
  • IPO Year
  • IMRN N/A
  • SPPL 2023
  • Fundamental
  • Price
  • IMRN $1.72
  • SPPL $3.50
  • Analyst Decision
  • IMRN Strong Buy
  • SPPL
  • Analyst Count
  • IMRN 1
  • SPPL 0
  • Target Price
  • IMRN $5.00
  • SPPL N/A
  • AVG Volume (30 Days)
  • IMRN 656.2K
  • SPPL 44.2K
  • Earning Date
  • IMRN 09-08-2025
  • SPPL 01-01-0001
  • Dividend Yield
  • IMRN N/A
  • SPPL N/A
  • EPS Growth
  • IMRN N/A
  • SPPL N/A
  • EPS
  • IMRN N/A
  • SPPL N/A
  • Revenue
  • IMRN $4,048,286.00
  • SPPL $2,764,846.00
  • Revenue This Year
  • IMRN N/A
  • SPPL N/A
  • Revenue Next Year
  • IMRN N/A
  • SPPL N/A
  • P/E Ratio
  • IMRN N/A
  • SPPL N/A
  • Revenue Growth
  • IMRN 82.90
  • SPPL N/A
  • 52 Week Low
  • IMRN $1.50
  • SPPL $2.02
  • 52 Week High
  • IMRN $2.87
  • SPPL $16.80
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 45.31
  • SPPL 60.28
  • Support Level
  • IMRN $1.60
  • SPPL $3.01
  • Resistance Level
  • IMRN $1.80
  • SPPL $3.45
  • Average True Range (ATR)
  • IMRN 0.10
  • SPPL 0.34
  • MACD
  • IMRN -0.01
  • SPPL 0.03
  • Stochastic Oscillator
  • IMRN 34.09
  • SPPL 56.60

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.

Share on Social Networks: